Multiple drug resistant organism (MDRO) infections are increasingly being treated in post-acute long-term care (PA-LTC) settings, due to high costs associated with treating MDRO in the hospital. While MDRO therapies are increasingly given in PA-LTC settings, studies suggest PA-LTCs may also be a reservoir of MDROs, perhaps more so than hospital settings. Intravenous antimicrobial agents effective against MDRO, such as vancomycin, must increasingly be provisioned to PA-LTC settings, but preparation time and cost of provisioning vancomycin is not well characterized in the literature.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the American Medical Directors Association
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2022 Published by Elsevier Inc.